SCHEMBL6487625

SCHEMBL6487625

C[C@H](NC(=O)OCc1ccccc1)C(=O)C(Cl)c1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 4/20 0.57
CTSK P43235 4/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSS P25774 1/20 0.47
ATM Q13315 1/20 0.46
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TOP2A P11388 2/20 0.45
TOP2B Q02880 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
KMT2A Q03164 1/20 0.45
TPSAB1 Q15661 2/20 0.45
PLG P00747 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29207429 0.83 CASP1 (0.63) CASP1ATMTOP2ATOP2BLMNA
SCHEMBL6500768 0.81 CASP1 (0.56) CASP1CTSKCTSLCTSSATM
SCHEMBL6501321 0.81 CASP1 (0.56) CASP1CTSKCTSLCTSSATM
SCHEMBL7141233 0.80 CASP1 (0.60) CASP1CTSKCTSLCTSBCTSS
SCHEMBL7109176 0.80 CASP1 (0.54) CASP1CTSKCTSLCTSBCTSS
SCHEMBL21225960 0.78 CASP1 (0.54) CASP1CTSKCTSLCTSBCTSS
SCHEMBL6571074 0.78 CASP1 (0.54) CASP1CTSKCTSLCTSBCTSS
SCHEMBL2397435 0.77 CASP1 (0.62) CASP1CTSKCTSLCTSBCTSS
SCHEMBL13168669 0.77 CASP1 (0.56) CASP1ATMALDH1A1TOP2ATOP2B
SCHEMBL20023002 0.76 EPHX2 (0.59) CASP1MEN1LMNAKMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6888012-B2 Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound AJINOMOTO CO., INC. (JP) 2005-05-03 US disclosed
US-20040082820-A1 Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals AJINOMOTO CO., INC. (JP) 2004-04-29 US disclosed
EP-1346972-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND Ajinomoto Co., Inc. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082820-A1 Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals DHPS, HDHD5, HYPK CASP1 3411/4885CTSK 505/4885CTSL 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.